Longitudinal Data Registry of Plasma Cell Dyscrasia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-99
SponsorShanghai Zhongshan Hospital
About this trial
This study aims to identify clinical characteristics, response and clinical outcome of plasma cell dyscrasia (PCD) diagnosed in Zhongshan Hospital, Fudan University from May 2023. In its current version, the registry incorporates historical data (collected from 2007) and is prospectively collecting follow-up data and recording patient outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients with pathological diagnosis of PCD from 2007 to 2027 according to 2016 WHO classification.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
2,000 Participants
are grouped into 1 trial groupGroup A: Enrolled patients
Trial outcomes
Primary outcomes
1
Overall survival
Overall survival (OS) refers to the time from receiving the first dose of regimen to death of any cause.
Time frame
From the time of enrollment to data cut-off (Up to approximately 20 years).Secondary outcomes
1
Progression-free survival
Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death of any cause, whichever occurs first.
Time frame
From the time of enrollment to data cut-off (Up to approximately 20 years).Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov